… Study Design This study is a multicenter, phase III study of the Korean Cancer Study Group
(KCSG; KCSG-BR07-02) with a randomized discontinuation design. Patients who achieved …

… agent paclitaxel as first-line chemotherapy in patients with … Paclitaxel was well tolerated
by patients in this study. Data from other clinical trials have shown that at a dosage of paclitaxel …

… The current GOG phase II chemotherapy trial uses docetaxel plus gemcitabine in … paclitaxel
might be considered; that regimen has reached first-stage accrual in a current phase II trial in …

… it into a phase III trial. The results of the present study provide a firm basis for the ongoing
phase III trial (GOG218), which also tests the hypothesis tested in this study that protracted …

… randomized, phase III trial, a … , paclitaxel, and cyclophosphamide (IDD-ETC) every 2 weeks
or conventionally scheduled epirubicin/cyclophosphamide followed by paclitaxel every three …

… /paclitaxel-based chemotherapy, were enrolled into this … rates across nonrandomized phase
II studies is hazardous, our … stabilization was 18 weeks in our study, quite reassuring in this …

… We conducted this phase II study to evaluate the efficacy and tolerability of this combination
… than grade II before receiving subsequent cycles of chemotherapy. Doses of paclitaxel and …

… -platinum versus platinum—was the only phase 3 trial in platinum-sensitive patients … trial
was substantial. Because platinum-paclitaxel is a global standard for primary therapy, our study …

… of standard doses of weekly iv paclitaxel, in which response … from a Japanese study of
3-weekly paclitaxel in a mixed … a randomized phase III trial of irinotecan versus paclitaxel every 4 …

… registered to this study 4-8 weeks after surgery. All patients were to receive 4 cycles of
paclitaxel 200 mg/m2 over 3 hours with carboplatin at an area under the curve of 6 every 3 weeks, …